114 related articles for article (PubMed ID: 33632098)
1. The Impact of Cell-free Plasma DNA on Metastatic and Nonmetastatic Prostate Cancer.
Abonar AA; Ayoub SE; Tagreda IA; Abdelhafez MN; Khamiss MM; Abdelaziz MI; Gaber SN; Amin A; Mohammed SR
Curr Mol Med; 2022; 22(1):67-73. PubMed ID: 33632098
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
3. Effect of NIH-IV prostatitis on free and free-to-total PSA.
Stancik I; Lüftenegger W; Klimpfinger M; Müller MM; Hoeltl W
Eur Urol; 2004 Dec; 46(6):760-4. PubMed ID: 15548444
[TBL] [Abstract][Full Text] [Related]
4. Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.
Stimac G; Spajic B; Reljic A; Katusic J; Popovic A; Grubisic I; Tomas D
Korean J Urol; 2014 Aug; 55(8):527-32. PubMed ID: 25132947
[TBL] [Abstract][Full Text] [Related]
5. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
6. Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy.
Stimac G; Reljic A; Spajic B; Dimanovski J; Ruzic B; Ulamec M; Sonicki Z; Kraus O
Scott Med J; 2009 Aug; 54(3):8-12. PubMed ID: 19725275
[TBL] [Abstract][Full Text] [Related]
7. [Aggressiveness and extent of prostatic inflammation relates with serum PSA levels in type IV prostatitis].
Man LB; Li GZ; Huang GL; Wang JW; Liu BY
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):710-4. PubMed ID: 22934516
[TBL] [Abstract][Full Text] [Related]
8. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Iran Biomed J; 2018 Sep; 22(5):331-7. PubMed ID: 29475366
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
11. Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk.
Battikhi MN; Hussein I
Int Urol Nephrol; 2006; 38(3-4):559-64. PubMed ID: 17318358
[TBL] [Abstract][Full Text] [Related]
12. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
[TBL] [Abstract][Full Text] [Related]
14. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
[TBL] [Abstract][Full Text] [Related]
16. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
[TBL] [Abstract][Full Text] [Related]
17. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
[TBL] [Abstract][Full Text] [Related]
18. The role of National Institutes of Health category IV prostatitis in accurately staging the newly diagnosed prostate cancer.
Aglamis E; Tasdemir C; Ceylan C
Ir J Med Sci; 2013 Sep; 182(3):463-7. PubMed ID: 23370973
[TBL] [Abstract][Full Text] [Related]
19. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
20. The significance of TPSA, free to total PSA ratio and PSA density in prostate carcinoma diagnostics.
Milkovic B; Hadzi-Djokic J; Dzamic Z; Pejcic T
Acta Chir Iugosl; 2007; 54(4):105-7. PubMed ID: 18595240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
